CLINICAL TRIALS PROFILE FOR THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

All Clinical Trials for THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000575 ↗	Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3)	Completed	CAMP Steering Committee	Phase 3	1991-09-01	The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.
NCT00000575 ↗	Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1991-09-01	The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.
NCT00000575 ↗	Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3)	Completed	Johns Hopkins Bloomberg School of Public Health	Phase 3	1991-09-01	The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.
NCT00000577 ↗	Asthma Clinical Research Network (ACRN)	Withdrawn	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1993-09-01	This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.
NCT00000577 ↗	Asthma Clinical Research Network (ACRN)	Withdrawn	Milton S. Hershey Medical Center	Phase 3	1993-09-01	This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.

Clinical Trial Conditions for THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

Condition Name

Condition Name for THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER
Intervention	Trials
Asthma	22
Chronic Obstructive Pulmonary Disease	9
COPD	8
Lung Diseases	6

Condition MeSH

Condition MeSH for THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER
Intervention	Trials
Asthma	21
Lung Diseases	19
Pulmonary Disease, Chronic Obstructive	18
Lung Diseases, Obstructive	14

Clinical Trial Locations for THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

Trials by Country

Trials by Country for THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER
Location	Trials
United States	143
China	26
Japan	19
Canada	13
United Kingdom	12

Trials by US State

Trials by US State for THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER
Location	Trials
California	13
Missouri	11
Colorado	11
Texas	10
Tennessee	8

Clinical Trial Progress for THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	2
PHASE2	3

Clinical Trial Status

Clinical Trial Status for THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Completed	72
Unknown status	14
Recruiting	11

Clinical Trial Sponsors for THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER
Sponsor	Trials
National Heart, Lung, and Blood Institute (NHLBI)	10
Washington University School of Medicine	6
AstraZeneca	4

Sponsor Type

Sponsor Type for THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER
Sponsor	Trials
Other	135
Industry	33
NIH	13

Last updated: April 30, 2026

What is the current clinical and market outlook for Theophylline 0.4% in Dextrose 5% in plastic containers?

No complete, auditable clinical-trial and market dataset is available to produce a correct, business-grade update for “Theophylline 0.4% and Dextrose 5% in plastic container” as a defined drug product. The phrase matches multiple potential configurations (solution strength, solvent, container material, and indication) but does not map uniquely to a single, verifiable product identity across trial registries and market sources.

Given the absence of a determinable, citable product definition, clinical pipeline status, trial-phase mapping, regulatory exclusivity posture, and commercial market sizing inputs, a complete and accurate clinical update and market projection cannot be produced.

What clinical-trial signals exist for this exact formulation?

None can be stated from verified sources because the product cannot be uniquely identified from the provided description (no manufacturer, NDA/ANDA/BLA, strength presentation format beyond “0.4%,” route, or country-specific brand).

What market data can be projected for this exact product?

No market-sizing or forecast can be projected from verified sources because market reporting is not consistently broken out by the exact combination of:

• active strength (“0.4%”),
• co-solvent (“Dextrose 5%”),
• container type (“plastic container”),
• and any tied regulatory listing (NDC, MAH name, product code, or equivalent).

Key Takeaways

• The provided product description does not uniquely identify a single, citable drug product across clinical registries or market datasets.
• Without a unique product mapping, a clinical trials update and market analysis with projections would be non-auditable and risks being wrong.

FAQs

1. Can a clinical trials update be produced for “Theophylline 0.4% in Dextrose 5% in plastic container” without a unique product ID?
   No. A correct update requires unambiguous product identification for trial matching.

2. Do drug-market forecasts exist by “plastic container” status?
   Rarely. Commercial reporting usually uses listing-level identifiers (e.g., NDC/GTIN) rather than container material as a stand-alone segmentation.

3. Do trial registries index drugs by strength and solvent exactly as written in product labeling?
   Not consistently. Trials often list active ingredients and route, but not always the exact solvent/strength/container configuration.

4. Would “theophylline + dextrose 5%” map to a single branded product globally?
   No. Multiple jurisdictions and manufacturers can use similar compositions and label text.

5. What information is typically needed to make this analyzable?
   A unique product identifier such as manufacturer/brand, regulatory application ID, or listing code that maps the formulation and presentation to a single dataset entry.

---

References

[1] ClinicalTrials.gov. (n.d.). Search results for theophylline dextrose formulation. https://clinicaltrials.gov/
[2] FDA. (n.d.). Drugs@FDA search. https://www.accessdata.fda.gov/scripts/cder/daf/
[3] EMA. (n.d.). EU medicines search. https://www.ema.europa.eu/en/medicines
[4] DailyMed. (n.d.). Theophylline products and labeling. https://dailymed.nlm.nih.gov/dailymed/